Dr. Mariam Oladejo, a distinguished Pharmaceutical Scientist specializing in Cancer Immunotherapy, is revolutionizing cancer research with her groundbreaking approach and innovative methodologies.
Dr. Oladejo, equipped with extensive training as a pharmacist and a Ph.D. in Immunotherapeutics and Biotechnology, is spearheading a new era in cancer treatment. Her impressive scientific portfolio includes significant contributions to cancer drug development, heralding a promising future for immunotherapy – a revolutionary approach utilizing the body’s immune system to combat cancer.
Driven by her passion for exploring alternative therapeutic avenues, Dr. Oladejo draws inspiration from traditional African ethnomedicine, which emphasizes the healing properties of natural agents. Reflecting on her journey, she states, “The belief in the healing power of nature ingrained in African ethnomedicine led me to investigate the neurological and anti-cancer effects of plant-based drugs during my undergraduate studies.”
During her graduate research at Texas Tech University Health Sciences Center, Dr. Oladejo focused on harnessing the potential of micro-organisms, particularly Listeria monocytogenes, notorious for its association with food poisoning, to develop cancer immunotherapies. Her pioneering work extends to elucidating the cellular mechanisms of cancer and enhancing immunity against malignancies, with notable contributions to cancer vaccine development and therapeutic target identification. She has continued to champion similar effort as a postdoctoral scientist in a world leading biopharmaceutical company.
With nearly five years of experience as a research scientist, Dr. Oladejo possesses a deep understanding of the intricate interplay between cancer and the tumor immune microenvironment. She has spearheaded investigations into cancer vaccines and immune checkpoint inhibitors for kidney and colon cancer, and is currently leading efforts to develop novel therapies for previously untreatable lung cancers.
Dr. Oladejo’s commitment to mentorship and scientific advocacy is evident in her efforts to champion microbe-based cancer therapeutics. She remains dedicated to nurturing the next generation of scientists and fostering enthusiasm for innovative approaches to cancer therapy.
Reflecting on the future of cancer treatment, Dr. Oladejo emphasizes the importance of understanding the genetic landscape of cancers to identify vulnerabilities. Leveraging cutting-edge techniques such as CRISPR-Cas9 genomic editing and protein degradation, she aims to develop novel immunotherapies targeting cancer vulnerabilities, paving the way for transformative advancements in cancer care.
“I am deeply passionate about harnessing the immune system’s potential to recognize genetic vulnerabilities in cancer,” Dr. Oladejo remarks. “My ultimate goal is to eradicate the scourge of cancer and alleviate the global public health burden.”
and then